Zismirt 30 mg Film-Coated Tablets

  • Name:

    Zismirt 30 mg Film-Coated Tablets

  • Company:
    info
  • Active Ingredients:

    Mirtazapine

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 29/05/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 3/6/2015
print

Print ViewKeyword Search SmPC

Gerard Laboratories

Gerard Laboratories

Company Products

Medicine NameActive Ingredients
Medicine Name Abacavir/Lamivudine Mylan 600 mg/300 mg film-coated tablets Active Ingredients Abacavir hydrochloride, Lamivudine
Medicine Name Agerdex 1mg Film Coated Tablets Active Ingredients Anastrozole
Medicine Name Agomelatine Mylan 25 mg film-coated tablets Active Ingredients Agomelatine
Medicine Name Amisulpride 50mg & 200mg Tablets Active Ingredients Amisulpride
Medicine Name Amlodipine Mylan 5mg & 10mg Tablets Active Ingredients Amlodipine besilate
Medicine Name Areloger 7.5mg & 15mg Tablets Active Ingredients Meloxicam
Medicine Name Aripil 5mg & 10mg Film-coated Tablets Active Ingredients Donepezil Hydrochloride
Medicine Name Atenetic 50/12.5mg & 100/25mg Film - coated Tablets Active Ingredients Atenolol, Chlortalidone
Medicine Name Atorvastatin Mylan 10 mg, 20 mg, 40 mg & 80 mg film-coated tablets Active Ingredients Atorvastatin calcium trihydrate
Medicine Name Atovaquone/Proguanil Hydrochloride 250 mg/100 mg film-coated tablets Active Ingredients Atovaquone, Proguanil Hydrochloride
Medicine Name Azromax 250mg Film-coated tablets Active Ingredients Azithromycin monohydrate
Medicine Name Baclopar Tablets 10 mg Active Ingredients Baclofen
Medicine Name Bisoprolol Mylan Active Ingredients Bisoprolol Fumarate
Medicine Name Brabio 20mg/ml solution for injection, pre-filled syringe Active Ingredients Glatiramer Acetate
Medicine Name Brabio 40mg/ml solution for injection, pre-filled syringe Active Ingredients Glatiramer Acetate
Medicine Name Cifloxager 250 mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Cifloxager 500 mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciprager 10mg & 20mg Film Coated Tablets Active Ingredients citalopram hydrobromide
Medicine Name Ciprager 40mg Film Coated Tablets Active Ingredients citalopram hydrobromide
Medicine Name Ciprofloxacin Mylan 2mg/1ml solution for infusion Active Ingredients Ciprofloxacin
Medicine Name Clopidogrel Mylan 75 mg film-coated tablets Active Ingredients clopidogrel hydrochloride
Medicine Name Darunavir Mylan 800 mg film-coated tablets Active Ingredients darunavir ethanolate
Medicine Name Depreger 50mg & 100mg Film-Coated Tablets Active Ingredients sertraline hydrochloride
Medicine Name Diaclide MR 30 mg Modified-release Tablets Active Ingredients Gliclazide
Medicine Name Diaclide MR 60mg modified-released tablets Active Ingredients Gliclazide
1 - 25 of 116 items.Total: 5 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 29 May 2018 PIL

Reasons for updating

  • Change to section 6 - what the product looks like and pack contents

Updated on 3 June 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 3 June 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 3 June 2015 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4 Special warnings and precautions for use
change heading from "Use in children and adolescents under 18 years of age:2 to Paediatric population

4.5 Interaction with other medicinal products and other forms of interaction
added:
Paediatric population
Interaction studies have only been performed in adults.

4.8 Undesirable effects
Side effects added:
Gastrointestinal disorders - Constipation (common)
Musculoskeletal and connective tissue disorders - Rhabdomyolysis (Not known)
Renal and urinary disorders - Urinary retention (Not known)
Investigations - Increased creatinine kinase (Not known)

4.9 Overdose
added:
Paediatric population
The appropriate actions as described for adults should be taken in case of an overdose in paediatrics.

5.3 Preclinical safety data
(red text added)
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.




(internal reference: DE/H/4373/IB046/G PR 557251)

Updated on 3 June 2015 PIL

Reasons for updating

  • Change of contraindications
  • Change to side-effects

Updated on 5 June 2014 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Addition of pancreatitis as a side effect

Updated on 27 May 2014 PIL

Reasons for updating

  • Change to side-effects

Updated on 20 August 2012 PIL

Reasons for updating

  • Change to instructions about overdose
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to dosage and administration
  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to instructions about missed dose

Updated on 15 May 2012 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Product information update following the Article 30 assessment of the reference product

 

Product information update following the assessment of a Periodic Safety Update Report
Inclusion of paediatric information following completion of the European paediatric work-sharing procedure

 

Updated on 15 May 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to instructions about missed dose
  • Change to side-effects
  • Change to information about drinking alcohol
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery

Updated on 16 November 2011 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to instructions about missed dose
  • Change to instructions about overdose
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to dosage and administration

Updated on 16 November 2011 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film coated tablet contains 30 mg of mirtazapine.

Excipient(s):
Each film-coated tablet contains 226.5mg lactose anhydrous and 1.8mg lactose monohydrate. For full list of
For excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet

A  normal convex, buff film coated tablet debossed ‘MR’ scoreline ‘30’ on one side and ‘G’ on the other.
The scoreline is onlt to facilitate breaking for ease of swallowing and not to divid into equal doses.


4.6 Pregnancy and lactation

Studies in animals have not shown any teratogenic effects or reproductive toxicity of any clinical relevance (see 5.3) The potential risk for women is unknown. Mirtazapine should not be used during pregnancy unless clearly indicated, following a careful risk/benefit consideration.
Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). Although no studies have investigated the association of PPHN to mirtazapine treatment, this potential risk cannot be ruled out taking into account the related mechanism of action (increase in serotonin concentrations).

Although animal experiments show that mirtazapine is excreted only in very small amounts in the milk, the use of mirtazapine in  breast feeding mothers is not recommended since no human data  about breast milk are available.

Updated on 13 August 2010 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Suicidal Warning included in Section 4.4 and 4.8

Section 4.4, paragraph added:

Suicide/suicidal thoughts or clinical worsening
Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.
Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.
Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.

Section 4.8, Suicial ideation and suicidal behaviour added

Psychiatric disorders

 

·         Suicidal ideation, suicidal behaviour.**) Frequency not known (cannot be estimated from the available data.)

 

 

·         Nightmares

·         Mania

·         Agitation

·         Confusion

·         Hallucinations

·         Anxiety *)

·         Insomnia *)

Updated on 1 February 2010 PIL

Reasons for updating

  • Change to date of revision
  • Change to improve clarity and readability
  • Change due to harmonisation of patient information leaflet

Updated on 15 February 2008 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 27 August 2007 PIL

Reasons for updating

  • Change to side-effects

Updated on 13 June 2007 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 
 Approval of increase in shelf life from 2 to 3 years

Updated on 4 September 2006 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 29 June 2005 PIL

Reasons for updating

  • New PIL for new product